Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 31, 1723-1729, November 1, 1971]
© 1971 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teillet, F.
Right arrow Articles by Bernard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teillet, F.
Right arrow Articles by Bernard, J.

A Reappraisal of Clinical and Biological Signs in Staging of Hodgkin's Disease

F. Teillet, M. Boiron1 and J. Bernard

Groupe d'étude sur la maladie de Hodgkin, Institut de Recherches sur les Leucémies et les Maladies du Sang, Hôpital Saint-Louis, Paris 10°, France

The current Rye classifcation no longer appears fully satisfactory for staging of Hodgkin's disease. As a result of a study of clinical, radiological, and biological data taken from the records of 402 patients from 1966 to 1970, we suggest that a new classification should take into account the following factors: the site of onset of the disease which enables a distinction between teh high cervical, mediastinal, retroperitoneal, and axillary forms, which all have their specific lymphatic extent; the involvement if any of the spleen; the biological signs as well as clinical symptoms for identification of the systemic syndrome. These changes could bring about significant consequences for therapy, especially in reducing irradiation volumes and in advocating the use of chemotherapy combined with radiotherapy.

1 Presented by.




This article has been cited by other articles:


Home page
JCOHome page
J. Landman-Parker, H. Pacquement, T. Leblanc, J. L. Habrand, M. J. Terrier-Lacombe, Y. Bertrand, Y. Perel, A. Robert, C. Coze, I. Thuret, et al.
Localized Childhood Hodgkin’s Disease: Response-Adapted Chemotherapy With Etoposide, Bleomycin, Vinblastine, and Prednisone Before Low-Dose Radiation Therapy--Results of the French Society of Pediatric Oncology Study MDH90
J. Clin. Oncol., April 7, 2000; 18(7): 1500 - 1507.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1971 by the American Association for Cancer Research.